Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-29T14:37:09.973Z Has data issue: false hasContentIssue false

1030 – Ocular Pigmentation And Cataract In Therapy With Phenothiazine

Published online by Cambridge University Press:  15 April 2020

D. Celona
Affiliation:
Psychiatric Clinic, University of Trieste, Trieste, Italy
S. Panarello
Affiliation:
Psychiatric Clinic, University of Trieste, Trieste, Italy
A. Zangrando
Affiliation:
Psychiatric Clinic, University of Trieste, Trieste, Italy
D. Carlino
Affiliation:
Psychiatric Clinic, University of Trieste, Trieste, Italy
M. De Vanna
Affiliation:
Psychiatric Clinic, University of Trieste, Trieste, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Since 1960, a decade after the introduction of phenothiazine drugs, there were reports of drug related ocular opacities and pigmentation in patients who had been receiving continuous high dose therapy, particularly with chlorpromazine. These ocular effects seem to be related to high doses of phenothiazines and are potentially irreversible. The purpose of our study is to evaluate the pathophysiology of ocular damage, risk factors, treatment and any potential reversibility.

Material and methods

Bibliographic research used PubMed and PsychINFO and conduced to 12 papers.

Results

Analysis of papers has shown that the main pathophysiological mechanism is related to an alteration of excretion of catecholamines, that exposure to sunlight presents a risk factor for the development of corneal deposits and cataract while, as regards the reversibility of these effects, the data are still controversial.

Conclusions

It is necessary, for psychiatrists, the information of the various ocular adverse effects of therapy with phenothiazine so that can be arranged to create a closer and more effective collaboration with an ophthalmologist to prevent and treat this disease.

Moreover, other studies are necessary to lead to an appropriate treatment plan.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.